Experts worry the warning on vaginal estrogen menopause treatments is doing more harm than good and is not supported by science.

A panel selected by FDA Commissioner Marty Makary, MD, MPH, unanimously urged the agency to remove the boxed warning on ...

On Thursday in Washington, D.C., the U.S. Food and Drug Administration (FDA) convened a panel of top experts to reassess the ...

Menopausal hormonal therapy, including estrogen alone and estrogen combined with progesterone, has been prescribed to help with those symptoms for decades. Hormones were also used to treat the ...

Members of an FDA expert panel discussed reassessing boxed warnings for menopausal HT and how to better educate patients and ...

The FDA is reconsidering the black box warning on estrogen. Experts say it’s time for a change—find out what this means for ...

A panel of 12 experts in the menopause field reexamined the findings of the 2002 Women’s Health Initiative study that said ...

A decades-old label has scared women (and their doctors) away from safe and effective menopause treatment. That could finally change today.

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

US health authorities on Thursday began a reassessment of the risks surrounding Hormone Replacement Therapy (HRT), a ...

US health authorities are set Thursday to reassess Hormone Replacement Therapy (HRT), a treatment used by menopausal women ...

Dr. Marty Makary, the agency’s commissioner, said too many women avoid hormone therapy because the risks have been overstated ...